IDEAYA Biosciences Inc
NASDAQ:IDYA

Watchlist Manager
IDEAYA Biosciences Inc Logo
IDEAYA Biosciences Inc
NASDAQ:IDYA
Watchlist
Price: 26.79 USD 0.71% Market Closed
Market Cap: 2.3B USD
Have any thoughts about
IDEAYA Biosciences Inc?
Write Note

Net Margin
IDEAYA Biosciences Inc

-4 541.6%
Current
-676%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 541.6%
=
Net Income
-178.1m
/
Revenue
3.9m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
IDEAYA Biosciences Inc
NASDAQ:IDYA
2.3B USD
-4 542%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
9%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
133.6B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.5B EUR
-14%
Country US
Market Cap 2.3B USD
Net Margin
-4 542%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 312.7B USD
Net Margin
9%
Country US
Market Cap 158.3B USD
Net Margin
13%
Country US
Market Cap 115.9B USD
Net Margin
-5%
Country US
Market Cap 112.4B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 133.6B AUD
Net Margin
18%
Country US
Market Cap 82.6B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.5B EUR
Net Margin
-14%
No Stocks Found

IDEAYA Biosciences Inc
Glance View

Market Cap
2.3B USD
Industry
Biotechnology

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2019-05-23. The firm is focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead synthetic lethality product candidate, IDE397, is a clinical-stage methionine adenosyltransferase 2a (MAT2A) inhibitor for patients with solid tumors having methylthioadenosine phosphorylase (MTAP) deletions. Its clinical-stage product candidate, darovasertib (IDE196), is a protein kinase C (PKC), inhibitor that is being evaluated as a synthetic lethal combination therapy in patients having genetically defined cancers having GNAQ or GNA11 gene mutations. Its pipeline also includes preclinical research programs directed to synthetic lethality targets PARG, Pol Theta, Werner Helicase, and certain deoxyribonucleic acid (DNA) damage targets. The PARG program is for patients having tumors with a defined biomarker based on genetic mutations.

IDYA Intrinsic Value
11.02 USD
Overvaluation 59%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 541.6%
=
Net Income
-178.1m
/
Revenue
3.9m
What is the Net Margin of IDEAYA Biosciences Inc?

Based on IDEAYA Biosciences Inc's most recent financial statements, the company has Net Margin of -4 541.6%.